For how we live.
Products promising to 'balance your hormones' lean on botanicals like maca, black cohosh and phytoestrogens, and on the hormone DHEA. When those ingredients are put in controlled trials, the evidence is limited or null.
Since 2024 the FDA has cleared over-the-counter CGMs for people who don't use insulin. The first independent accuracy check in adults without diabetes finds the sensors track the trend but miss the exact number.
A dormant breach-notification rule became an enforcement tool in 2023, when the FTC fined GoodRx and BetterHelp for sharing users' health data with ad platforms. A 2024 rule change locked apps into its reach.
Commercial full-body scans promise early detection to people with no symptoms. The data show they find something to chase in nearly half, and cancer in about one in a hundred.
The puffy 'cortisol face' and the 'cortisol cocktails' sold to fix it lean on 'adrenal fatigue' — a condition a systematic review of 58 studies found no evidence for. True cortisol excess is a diagnosable disease.
In a study of 750 women, those with 'low' ovarian-reserve hormones were no less likely to conceive. Professional guidance says the test shouldn't be used to counsel women who aren't already infertile.
A pandemic waiver letting clinicians prescribe stimulants and other controlled medicines without an in-person visit has been extended a fourth time, to end-2026, with the permanent framework still a proposal.
23andMe's cleared BRCA report reads 3 of more than 1,000 mutations, so a negative result is not the all-clear it looks like — and the firm's bankruptcy has put customers' genetic data in play.
Researchers searched in four languages across three engines. One in ten clinics said it would prescribe testosterone to men with normal levels; one in five claimed it cuts cardiovascular risk.
A systematic review screened 3,857 records and found three eligible studies, every one produced by a US commercial provider and every one at critical risk of bias.
An audit of 17 manufacturers' privacy policies found transparency the weakest area, with wide variation between brands. The data these devices generate largely falls outside HIPAA and GDPR's clinical protections.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.